38 results
8-K
EX-99.1
PASG
Passage Bio Inc
7 Aug 23
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7:15am
accumulation of toxic GM1 gangliosides and reverse neuronal toxicity, thereby restoring developmental potential. In preclinical models, PBGM01 has … of toxic levels of GM1 gangliosides in neurons throughout the brain, causing rapidly progressive neurodegeneration. GM1 accumulation also results
8-K
EX-99.2
PASG
Passage Bio Inc
7 Aug 23
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7:15am
. By increasing beta-galactosidase activity, PBGM01 has the potential to reduce accumulation of toxic GM1 gangliosides and reverse neuronal toxicity, thereby … -galactosidase (β-gal). Reduced β-gal activity results in the accumulation of toxic levels of GM1 gangliosides in neurons throughout the brain, causing
8-K
EX-99.1
n0o117ochpx q9dyw
14 Dec 22
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
7:00am
8-K
ez2073 hf4lk1qmb
8 Jun 22
Other Events
7:44am
8-K
EX-99.1
h5im9r7
18 May 22
Passage Bio Presents New Interim Clinical and Biomarker
7:16am
8-K
EX-99.2
i4fvgg1vfd8c3d88uyz
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
8-K
EX-99.1
eukadz3t1
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
xrxe l5ylecgq
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
nng31bsuee3zcta7
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.1
vxt3a283ywq6sdi uir
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am